ArticleCell insight2026
XPO1 coordinates human cytomegalovirus maturation by modulating genome encapsidation and secondary envelopment.
Article in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cytomegalovirus (HCMV) replication depends on tightly coordinated nuclear capsid assembly and cytoplasmic nucleocapsid maturation, yet host factors controlling these processes remain poorly defined. Here, we identify exportin 1 (XPO1) as a dual-phase regulator that coordinates HCMV maturation from nucleus to cytoplasm. XPO1 inhibition induces aberrant nuclear electron-dense speckles and accumulation of B-capsids. Mechanistically, nuclear retention of pp65 drives speckle formation but does not account for B-capsid accumulation. XPO1 recognizes a functional nuclear export signal (NES) within pUL77 and regulates its proper intranuclear localization. Inhibiting XPO1 or disrupting the NES induces intranuclear pUL77 aggregation and B-capsid accumulation. XPO1 is also required for viral assembly compartment formation and maintenance of late-stage autophagic flux, both of which are essential for secondary envelopment. Our findings highlight the key role of XPO1 in virion maturation and the therapeutic potential of repurposing FDA-approved XPO1 inhibitors as a host-directed antiviral strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.